Merck & Co and Pfizer release new combo data for their investigational SGLT2 inhibitor at the ADA – combinations will be key to the latecomer's overall success.
New data for Merck & Co. Inc. and Pfizer Inc.'s SGLT2 inhibitor in ertugliflozin in combination with metformin reported at the American Diabetes Association meeting in San Diego complete the set for this fourth-in-class product, which is currently under regulatory review.
While it will enter a competitive market, ertugliflozin should be able to carve out a niche with its combinations with...
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
